ERBB2 and breast cancer: However, the result derived from this cohort is consistent with the common consensus that 1) higher T and N stages increase the likelihood of distant metastasis; 2) adjuvant treatments decrease the likelihood of distant metastasis; 3) triple-negative, HER2, and luminal-B subtypes are more aggressive than luminal-A breast cancer with higher 18-gene scores and recurrence rates (Table 2).